Categories
Change Password!
Reset Password!
This prospective, observational, real-life study was carried to determine the efficacy of mepolizumab (anti-interleukin-5 monoclonal antibody) on sino-nasal symptoms, polyp growth, and asthma control in asthma patients having chronic rhinosinusitis and nasal polyposis.
In individuals having severe eosinophilic asthma and
concomitant chronic rhinosinusitis and nasal polyposis, mepolizumab leads to
improvement in sino-nasal and asthma symptoms and minimizes polyp growth.
This
prospective, observational, real-life study was carried to determine the
efficacy of mepolizumab (anti-interleukin-5 monoclonal antibody) on sino-nasal
symptoms, polyp growth, and asthma control in asthma patients having chronic
rhinosinusitis and nasal polyposis.
The 12-month study incorporated 44 asthma subjects suffering from chronic rhinosinusitis and nasal polyposis in real life. Participants were treated with subcutaneously administered mepolizumab (100 mg every four weeks) for one year. The endpoints were evaluated before (T0), after six (T6) and 12 months (T12) of therapy: Asthma control test (ACT), forced expiratory volume at 1 sec (% FEV1), Total Endoscopic Nasal Polyp Score (TENPS), and sino/nasal outcome test (SNOT-22).
Also, blood
eosinophil count, prednisone consumption, and fractional exhaled nitric oxide
(FENO) were estimated. In a subgroup of participants, the nasal cytology was
conducted before, after six, and 12 months of mepolizumab therapy.
There was a substantial decline of SNOTT-22 and TENPS from the baseline. The nasal cytology findings indicated a considerable decrease of eosinophil percentage after mepolizumab treatment, as shown in Table 1:
Remarkable
improvements of % FEV1 and ACT, and a decline in blood eosinophils and mean
prednisone consumption were also witnessed. For FENO, there was no vital
decreasing trend.
Mepolizumab used in a real-life setting to treat severe
eosinophilic asthma improves sino-nasal and asthma outcomes, minimizes polyp
growth, and exerts a steroid-sparing effect in patients with concomitant chronic
rhinosinusitis and nasal polyposis.
Therapeutic advances in respiratory disease
Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study
Aikaterini Detoraki et al
Comments (0)